scholarly journals Expression of P53, PTEN and S100A4 in invasive ductal breast cancer and the clinical significance

2015 ◽  
Vol 6 (6) ◽  
pp. 43-47 ◽  
Author(s):  
Zhang Gang ◽  
Li Zhong ◽  
Lin Xiao-meng ◽  
Zhang Jun-hua ◽  
Cui Yong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Breast Lesions ◽  
Clinical Grade ◽  
Invasive Ductal Breast Cancer ◽  
Node Metastasis ◽  
Ductal Breast Cancer ◽  
Benign Breast Lesions

Objective: To investigate the expression level of P53, PTEN and S100A4 in invasive ductal breast cancer and the clinical significance. Methods: SP immunohistochemical and Western blot analysis were used to detect the expression of P53, PTEN and S100A4 protein in invasive ductal breast cancer, adjacent tissues and benign breast lesions. The results were aimed to explore the correlation of p53, PTEN, S100A4 and analyze the relationship between indicators and clinical pathology. Results: Immunohistochemical results showed that the positive rates of p53 and S100A4 in invasive ductal breast cancer were 47.69% and 56.92%, which were significantly higher than that in benign breast lesions (16.00%, 22.00%) (p<0.05); The positive rates of PTEN in invasive ductal breast cancer was 24.62%, which were significantly lower than that in benign breast lesions (52.00%) (p<0.05); The expression of p53 was negatively correlated with PTEN in invasive ductal breast cancer (p<0.05). Western blot results revealed that the relative expression levels of p53, PTEN and S100A4 protein in invasive ductal breast cancer were 0.967±0.066, 0.785±0.044, 1.065±0.073, which were significant difference with that in benign breast lesions (0.549±0.032, 1.245±0.059, 0.370±0.065) (p<0.05); The expression of p53 has correlation with histological differentiating degree and lymph node metastasis (p<0.05), but it was irrelevant to the age, tumor size and clinical grade (p>0.05). The expression of S100A4 has correlation with clinical grade and lymph node metastasis (p<0.05), but no association with the age, tumor size and histological differentiating degree was observed in this study (p>0.05). The expressions of PTEN has correlation with lymph node metastasis p<0.05, but no association with the age, tumor size, clinical grade and histological differentiating degree was noted in our study (p>0.05). Conclusion: Expression of P53, PTEN and S100A4 can be expected to be taken as to the prognosis biomarkers of breast cancer and potential targets for new and effective treatment strategies for breast cancer.DOI: http://dx.doi.org/10.3126/ajms.v6i6.12599 Asian Journal of Medical Sciences Vol.6(6) 2015 43-47

scholarly journals Expression of P53, PTEN and S100A4 in invasive ductal breast cancer and the clinical significance

2017 ◽  
Vol 6 (2) ◽  
pp. 49-55
Author(s):  
Z Gang ◽  
L Zhong ◽  
L Xiao-meng ◽  
Z Jun-hua ◽  
C Yong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumour Size ◽  
Breast Lesions ◽  
Clinical Grade ◽  
Invasive Ductal Breast Cancer ◽  
Node Metastasis ◽  
Ductal Breast Cancer ◽  
Benign Breast Lesions

Objective: To investigate the expression level of P53, PTEN and S100A4 in invasive ductal breast cancer and the clinical significance. Methods: SP immunohistochemical and Western blot analysis were used to detect the expression of P53, PTEN and S100A4 protein in invasive ductal breast cancer, adjacent tissues and benign breast lesions. Results: Immunohistochemical results showed that the positive rates of P53 and S100A4 in invasive ductal breast cancer were 47.69% and 56.92%, which were significantly higher than that in benign breast lesions 16.00% and 22.00% respectively (P<0.05） while positive rates of PTEN in invasive ductal breast cancer was 24.62%, compared to benign breast lesions 52.00%（P<0.05). The expression of P53 was negatively correlated with PTEN in invasive ductal breast cancer（P<0.05). Western blot revealed that the relative expression levels of P53, PTEN and S100A4 protein in invasive ductal breast cancer were 0.967±0.066, 0.785±0.044 and 1.065±0.073 respectively, which were significantly different with that in benign breast lesions （0.549±0.032, 1.245±0.059, 0.370±0.065）（P<0.05). The expression of P53 can be correlated with histological grading and lymph node metastasis（P<0.05), but not with tumour size and clinical grade (P>0.05) While expression of S100A4 has correlation with clinical grade and lymph node metastasis（P<0.05), but no association with the age, tumour size and histological differentiating degree was observed（P>0.05). Similarly, expressions of PTEN has relation with lymph node metastasis (P<0.05), but not with the age, tumor size, clinical grade and histological grading was noted in our study（P>0.05). Conclusion: Expression of P53, PTEN and S100A4 can be taken as to the prognosis biomarkers of breast cancer and potential targets for new and effective treatment strategies for breast cancer. 

HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer

Tumor Biology ◽  
2013 ◽  
Vol 34 (6) ◽  
pp. 3611-3617 ◽  
Author(s):  
Yongxiang Yin ◽  
Man Wu ◽  
Guiying Nie ◽  
Ke Wang ◽  
Jia Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Invasive Ductal Breast Cancer ◽  
Node Metastasis ◽  
Ductal Breast Cancer

Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients

2008 ◽  
Vol 134 (11) ◽  
pp. 1229-1235 ◽  
Author(s):  
Sebastian Mayer ◽  
Axel zur Hausen ◽  
Dirk Otto Watermann ◽  
Stefan Stamm ◽  
Markus Jäger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Node Metastasis ◽  
Soluble Cd44

Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 20-20
Author(s):  
Inhye Park ◽  
Jiyoung Kim ◽  
Se-Kyung Lee ◽  
Min-Young Choi ◽  
Su Yeon Bae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Invasive Ductal Carcinoma ◽  
Tumor Size ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Clinicopathologic Features ◽  
Node Metastasis

20 Background: Medullary carcinoma (MC) represents a rare breast cancer subtype associated with a rather favorable prognosis compared with invasive ductal carcinoma (IDC). It is characterized by the high-grade structure and lymphocytic infiltration, hemorrhagic necrosis. The purpose of this study is to compare the clinicopathologic characteristics and outcome of MC to IDC. Methods: We retrospectively reviewed the medical records of patients with invasive breast cancer managed with operation at Samsung Medical Center in Korea from January 1995 to June 2010 except patients diagnosed with ductal carcinoma in situ, patients with distant metastasis at diagnosis or neoadjuvant chemotherapy. 52 cases were identified with MC; 5,716 patients with IDC. The clinicopathologic features, disease-free survival (DFS) and overall survival (OS) for patients with MC were compared with those of the IDC patients. Results: The medullary group presented at younger age (43.9 ± 8.8 vs 47.7 ± 9.9, p=0.006). Also the medullary group was significantly associated with higher histological grade (poor; 80.0 vs 38.3%, p=0.003) and nuclear grade (grade3; 82.8 vs 41.7%, p<0.001) as well as negative ER (84.8 vs 31.0%, p<0.001) and PR status (91.3 vs 38.8%, p<0.001) regarded as poor prognostic factors. But lymphatic invasion was rare (0.0 vs 29.8%, p<0.001) and N stage was low (N0; 86.5 vs 58.4%, p<0.001). The DFS and OS were not significantly different between the medullary and IDC groups. (5-yr DFS : 88.0 vs 89.2 %, p=0.917, 5-yr OS : 94.4 vs 93.4%, p=0.502) In multivariable analysis, factors associated with DFS and OS included nuclear grade, histological grade, tumor size, lymph node metastasis, ER/PR/C-erbB2 status, chemotherapy and hormone therapy. When adjusting for other factors, histological type itself did not show significant difference from IDC in DFS and OS. Conclusions: Despite MC present specific clinicopathologic features, prognosis is not different from IDC and determined by already known prognostic factors such as tumor size, lymph node metastasis. Therefore, the patients with MC also need aggressive treatment like IDC.

Sign in / Sign up

Export Citation Format

Share Document